Benzinga | Dec 6, 2021 04:50PM EST

Precision BioSciences To Host Webcast, Conference Call On Saturday, Dec. 11, 2021 To Review Interim Phase 1/2a Data For Its CAR-T Cell Candidate

Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage biotechnology company using its ARCUS(r) genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced it will review interim data results presented at the 63rd American Society of Hematology Annual Meeting from the PBCAR0191 CD19 allogeneic CAR T program and provide other CAR T program updates during a company-hosted webcast and conference call on Saturday, December 11, 2021 at 7:30 PM ET.

Precision previously announced that abstracts accepted by ASH are now available at www.hematology.org, and the following two abstracts will be presented during oral presentation sessions:

Oral Presentation: #626. Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion is Highly Active in Subjects with Relapsed/Refractory B-cell Malignancies (Abstract #302)

Presenting Author: Bijal Shah, M.D., Moffitt Cancer Center

Date/Time/Location: Saturday, December 11, 2021 at 4:15 PM ET in the Georgia World Congress Center, B401-B402

Oral Presentation: #704. Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic 'Off-the-Shelf' CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL (Abstract #650)

Presenting Author: Nitin Jain, M.D., The University of Texas MD Anderson Cancer Center

Date/Time/Location: Monday, December 13, 2021 at 10:45 AM ET in the Georgia World Congress Center, Sidney Marcus Auditorium